Solaiman Shereen 4

What Happened Shereen Solaiman, Chief People Officer of Myriad Genetics (MYGN), was granted 173,196 restricted stock units (RSUs) on March 12, 2026 (no cash paid). To satisfy tax withholding when RSUs vested, the issuer withheld 8,899 shares on March 13, 2026 (reported disposed at $4.66 each, $41,469) and 5,784 shares on March 14, 2026 (reported disposed at $4.66 each, $26,953). The two withholdings total 14,683 shares and approximately $68,422 in value.

Key Details

• Grant: 173,196 RSUs on 2026-03-12 (reported as Award/Acquisition, code A; acquisition price $0.00).
• Withholdings: 8,899 shares on 2026-03-13 and 5,784 shares on 2026-03-14 (reported as tax withholding, code F) at $4.66 per share.
• Total withheld/disposed value: $41,469 + $26,953 = $68,422 (per filing).
• Shares owned after transaction: not disclosed in the provided filing details.
• Footnotes: F1 — RSUs are time-based and vest in three equal annual installments beginning on the first anniversary of the grant. F2 — The number of shares withheld was determined based on Myriad's closing price on March 13, 2026.
• Filing: Form 4 filed March 16, 2026 reporting transactions dated March 12–14, 2026 (no late-filing flag included in the provided data).

Context This was primarily an equity grant (RSUs) with routine share withholding to cover tax liabilities when those units vested. The withheld shares are not open-market sales by the insider for personal liquidity; they are a common employer withholding method and do not by themselves signal a vote of confidence or lack thereof. The RSUs vest over three years starting one year after the grant, so additional vesting events (and possible withholding) may occur in future reporting.